s | 3 of adverse effects that currently limit the use of opioids in the clinic. Supported by USPHS Grant K05DA017918 PM288 Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction Eliot L. Gardner1, Guo-Hua Bi1, Ganesh Thakur2, Alexandros Makriyannis2, Herbert H. Seltzman3, Xiang-Hu He4, Zheng-...